Endocrine Abstracts

BRAFV600E mutation is considered useful in recognizing thyroid cancer aggressiveness or poor prognosis particularly in certain variants of papillary thyroid cancinoma (PTC). A recent meta-analysis identified 12 cancer-versus-non cancer gene candidate as markers of thyroid cancer; among these TIMP-1 (tissue inhibitors of metalloproteinases) was found consistently up-regulated. Our aim was to evaluate BRAFV600E mutation and TIMP-1 expression in 14 PTC class...